M. ZEBELMAN, 5 and MARGARET A. KENNY2 to manufacturers' specifications. Quality-assurance measure indicated that the analyses were "in control" for the measurements quoted.
Results
In the first phase of the study, the prototype ACS Digoxin assa was evaluated for accuracy, precision, sensitivity, and genera performance.
The assay kit came with a six-point "master curve'
and was calibrated by using two calibrators witi However, the maximum observed discrepancy (without bias correction) was 1.9 .tg/L digoxin. In Fig. 2 (top Fig. 1E shows the results for digoxin-free heart surgery patients (n = 16). Both the ACS and the TDx reagents gave negative results for this group's sera, whereas the Stratus method had 13 apparent DLIF measurements greater than the method's sensitivity limit.
Discussion
We have examined the specificity of three digoxin immunoassays towards some commonly found digoxin metabolites and analogs, assaying sera of patient groups commonly associated with a high frequency of DLIF. Of the three automated digoxin assays tested, TDx, Stratus, and ACS, the latter was the least affected among all 12 of the digoxin-free DLIF cohorts (total 229 patients) tested. The difference in DLIF specificity among the three assays could be explained by the use of very specific monoclonai antibody in the ACS assay (the other two assays had polyclonal rabbit antibodies).
We also found three different patterns of interference among these cohorts with respect to the assays affected. 
